Inovio Pharmaceuticals, Inc.INONASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, below historical average, slight contraction.
Left:
||||
Year-over-year net income growth rate
Latest
-93.44%
↓ 128% below average
Average (39q)
-40.91%
Historical baseline
Range
High:114.90%
Low:-420.89%
CAGR
-3.8%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -93.44% |
| Q2 2025 | -19.42% |
| Q1 2025 | -1.62% |
| Q4 2024 | 22.98% |
| Q3 2024 | 21.94% |
| Q2 2024 | -5.80% |
| Q1 2024 | -21.86% |
| Q4 2023 | 26.31% |
| Q3 2023 | 4.52% |
| Q2 2023 | 12.58% |
| Q1 2023 | 25.36% |
| Q4 2022 | -44.14% |
| Q3 2022 | 65.18% |
| Q2 2022 | -37.21% |
| Q1 2022 | 26.06% |
| Q4 2021 | -77.75% |
| Q3 2021 | 26.75% |
| Q2 2021 | -50.99% |
| Q1 2021 | -123.52% |
| Q4 2020 | -226.95% |
| Q3 2020 | 114.90% |
| Q2 2020 | -295.51% |
| Q1 2020 | 13.60% |
| Q4 2019 | -63.10% |
| Q3 2019 | 21.43% |
| Q2 2019 | -0.57% |
| Q1 2019 | 11.36% |
| Q4 2018 | -31.77% |
| Q3 2018 | -276.79% |
| Q2 2018 | 79.48% |
| Q1 2018 | -50.43% |
| Q4 2017 | 37.00% |
| Q3 2017 | -260.10% |
| Q2 2017 | 58.94% |
| Q1 2017 | 12.00% |
| Q4 2016 | -26.37% |
| Q3 2016 | -10.98% |
| Q2 2016 | -132.56% |
| Q1 2016 | 55.20% |
| Q4 2015 | -420.89% |